• Product NameErdafitinib
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityErdafitinib is a quinoxaline derivative compound, acts on FGFR1/2/3/4 with mean pIC50 of ~ 9/8.5/8.5/8.25, respectively.
• Target NameFGFR inhibitor
• CAS No. 1346242-81-6
• Calculated MW 446.55
• Formulation C25H30N6O2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC(NCCN(C1=CC(OC)=CC(OC)=C1)C2=CC=C3N=CC(C4=CN(C)N=C4)=NC3=C2)C
  Pathways:Angiogenesis; Tyrosine Kinase/Adaptors
  Receptor:FGFR1; FGFR2; FGFR3; FGFR4
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 89 mg/mL (199.31 mM); DMSO:89 mg/mL (199.31 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1.Timothy Perera, et al. Cancer Res. 2014, 74(19 Suppl):Abstract nr 1738. [2] Verstraete M, et al. BMC Cancer. 2015, 15:946.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting